
    
      To assess the hypothesis that this new 2nd generation positron emission tomography (PET)
      radiopharmaceutical, 18F-DCFPyL, may possess pharmacokinetic and pharmacodynamic properties
      that will represent an advance in imaging metastatic prostate cancer in ten patients
      diagnosed with metastatic prostate cancer.
    
  